Is drug-induced toxicity a good predictor of response to neo-adjuvant chemotherapy in patients with breast cancer? -A prospective clinical study

BMC Cancer

Volumn 4, Issue , 2004, Pages

  Chintamani, A ^a,b   Singhal, Vinay ^a,b   Singh, J P ^a,b   Lyall, Ashima ^a,b   Saxena, Sunita ^a,b   Bansal, Anju ^a,b  

^a SAFDARJUNG HOSPITAL CAMPUS   (India)

^b SAFDARJUNG HOSPITAL   (India)

Author keywords

Apoptosis; Drug toxicity; Neoadjuvant chemotherapy; Response

Indexed keywords

CYCLOPHOSPHAMIDE; DNA; DOXORUBICIN; FLUOROURACIL; PROTEIN BAX; PROTEIN BCL 2; ANTINEOPLASTIC AGENT; BAX PROTEIN, HUMAN;

ADULT; ADVANCED CANCER; AGED; ALOPECIA; APOPTOSIS; ARTICLE; BREAST BIOPSY; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER PATIENT; CELL DEATH; CHI SQUARE TEST; CLINICAL ARTICLE; CLINICAL EXAMINATION; CONTROLLED STUDY; CORRELATION ANALYSIS; CORRELATION COEFFICIENT; COST EFFECTIVENESS ANALYSIS; DNA DAMAGE; DRUG INDUCED DISEASE; FEMALE; HUMAN; IMMUNOHISTOCHEMISTRY; INDIVIDUALIZATION; LEUKOPENIA; MASTECTOMY; MEDICAL ASSESSMENT; METASTASIS POTENTIAL; MULTIMODALITY CANCER THERAPY; PATIENT CARE; PREDICTION; PROSPECTIVE STUDY; PROTEIN EXPRESSION; RELIABILITY; TREATMENT FAILURE; TREATMENT OUTCOME; TUMOR CELL; TUMOR VOLUME; VOMITING; ADJUVANT CHEMOTHERAPY; ADJUVANT THERAPY; BREAST TUMOR; CARCINOMA; CHEMICALLY INDUCED DISORDER; DRUG EFFECT; LYMPH NODE METASTASIS; METABOLISM; METASTASIS; MIDDLE AGED; NEEDLE BIOPSY; PATHOLOGY;

ADULT; AGED; ALOPECIA; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; APOPTOSIS; BCL-2-ASSOCIATED X PROTEIN; BIOPSY, NEEDLE; BREAST NEOPLASMS; CARCINOMA; CHEMOTHERAPY, ADJUVANT; CYCLOPHOSPHAMIDE; DOXORUBICIN; FEMALE; FLUOROURACIL; HUMANS; IMMUNOHISTOCHEMISTRY; LYMPHATIC METASTASIS; MASTECTOMY; MIDDLE AGED; NEOADJUVANT THERAPY; PROSPECTIVE STUDIES; PROTO-ONCOGENE PROTEINS C-BCL-2; TREATMENT OUTCOME; VOMITING;

EID: 13144297795     PISSN: 14712407     EISSN: None     Source Type: Journal    
DOI: 10.1186/1471-2407-4-48     Document Type: Article

References (30)

1. Paymaster JC: Cancer of the breast in Indian Women. Surgery 1956, 40:372-376.
2. Ellis PA, Smith IE, Detre S, Burton SA, Salter J, Hern A, Walsh G, Johnston SRD, Dowsett M: Reduced apoptosis and proliferation and increased Bcl-2 in residual breast cancer following preoperative chemotherapy. Breast Cancer Research and Treatment 1998, 48: 07-116.
3. Kerr JF, Winterford CM, Hormon BV: Apoptosis: its significance in cancer and cancer therapy. Cancer 73(8 : 013-2026. 1994 Apr 15
4. Hahm HA, Davidson NE: Apoptosis in the mammary gland and breast cancer. Endocrine Related Cancer 1998, 5:199-211.
5. Jussawala DJ, Yeole BB, Natekar MV, Narayan RA: Epidemiology of breast cancer in India. Indian J Cancer 1978, 12:231-242.
6. Frassoldati A, Adami F, Banzi C, Criscuolo M, Piccinini L, Silingardi V: Changes of biological features in breast cancer cells determined by primary chemotherapy. Breast Cancer Res And Treat 1997, 44:185-192.
7. Oltvai ZN, Milliman CL, Korsmeyer SJ: Bcl-2 heterodermize in vivo with a conserved homologue, bax, that accelerates programmed cell death. Cell 1993, 74:609-615.
8. Hockenbery DM, Nunez G, Milliman : Bcl-2 is an inner mitochondrial membrane protein that blocks programmed cell death. Nature 1990, 348:334-336.
9. Bargou RC, Daniel PT, Mapara MY, Bommert K, Wagener C, Kallinich B, Royer HD, Dorken B: Expression of the bcl-2 gene family in normal and malignant breast tissue: low bax expression in tumor cells correlates with resistance towards apoptosis. Int J Cancer 1995, 60:844-859.
10. Eltahir A, Heys SD, Hutcheon AW, Sarkar TK, Smith I, Walker LG, Ah-See AK, Eramin O: Treatment of large and locally advanced breast cancer using neoadjuvant chemotherapy. Am J Surg 1996, 175:127-132.
11. Bonadonna G, Valagussa P, Zambetti M: Locally advanced breast cancer: 10 year results after combined treatment. Proceed Am Soc Clin Oncol 1988, 7:9.
12. Buzdar A, Singletary S, Booser D: Combined modality treatment for stage III and inflammatory carcinoma of the breast. M.D. Anderson Cancer Center experience. Surg Oncol Clin North Am 1995, 4:715.
13. Singh G, Singh DP, Gupta D: Neoadjuvant chemotherapy in locally advanced breast cancer. J Surg Oncol 1996, 61: 8-41.
14. Blomqvist C, Elomma I, Rissanen P: Influence of treatment schedule on toxicity and efficacy of cyclophosphamide, epirubicin and flouracil in metastatic breast cancer-a randomized trial comparing weekly and every four week administration. J Clin Oncol 1993, 11: 67-473.
15. Kymionis GD, Dimitrakakis CE: Can expression of apoptosis genes, bcl-2 and bax predict survival and responsiveness to chemotherapy in node negative breast cancer patients? J Surg Res 2001, 99: 61-168.
16. Searle J, Lawson TA, Abbott PJ: An electron mocroscope study of the mode of cell death induced by cancer chemotherapeutic agents in populations of proliferating normal and neoplastic cells. J Pathol 1975, 116:129-138.
17. Nabusada Shinoura, Yoko Yoshida, Miyako Nishimura, Yukiko Muramatsu, Akio Asai, Takaaki Kirino, Hirofumi Hamada: Expression of BCL-2 Determines Anti- or Proapoptotic Function. Cancer Research 59:4119-4128. August 15 1999.
18. Perez P, Presant C, Philpott G: Phase I-II study of concurrent and multi drug chemotherapy in advanced carcinoma of breast: a pilot study by the south-eastern cancer study group. Int J Radiat Oncol Biol Phys 1979, 5:1329.
19. Fisher B, Brown A, Mamounas E, et al.: Effect of preoperative chemotherapy of loco regional disease in women with operable cancer-Findings from National Surgical Adjuvant Breast and Bowel Project B-18. J Clin Oncol 1997, 15:2483-2493.
20. El-Didi MH, Moneer MM, Khaled HM: Pathological assessment of response of locally advanced breast cancer to neo adjuvant chemotherapy and its implication for surgical management. Surg Today 2000, 30:249-254.
21. Diadone MG, Silverstrini R, Luisi A: Changes in biological markers after primary chemotherapy in breast cancers. Int J Cancer 1995, 61:301-305.
22. Mamounas EP, Fisher B: Preoperative (neoadjuvant) chemotherapy in patients with breast cancer. Semin Oncol 2001, 28:389-399.
23. Thor AD, Reed JC, Sato T: Immunohistochemical analysis of bax and bcl-2 in p53 immunosuppressive breast cancers. US Canad Acad PatholAbst 1996, 26 A:132-135.
24. Miyashita T, Reed JC: Bcl-2 gene transfer increases relative resistance of 549.1 and WEH 17.2 lymphoid cells to cell death and DNA fragmentation induced by glucocorticoids and multiple chemotherapeutic drugs. Cancer Res 1992, 52:5407-5410.
25. Wyllie AH, Kerr JFR, Curie AR: Cell death-the significance of apoptosis. Internat Rev Cytol 1980, 68:251-304.
26. Sakakura C, Sweeny EA, Shirahama , et al.: Overexpression of bax sensitizes human breast cancer MCF-7 to radiation induced apoptosis. Int J Cancer 1996, 67:101-105.
27. Krajewski S, Krajewska M, Shabaik A: Immunohistochemical determination of bax a dominant inhibitor of bcl-2. Amer J Pathol 1994, 145:1323-1336.
28. Feuerhake F, Sigg W, Hofter EA: Cell proliferation, apoptosis and expression of bcl-2 and bax in non lactating human breast epithelium in relation to the menstrual cycle and reproductive history. Breast Cancer Res Treat 2003, 77:37-48.
29. Rasbridge SA, Gillett CE, Seymour AM: The effect of chemotherapy on morphology, cellular proliferation, apoptosis oncoprotein expression in primary breast carcinoma. Br J Cancer 1994, 70: 35-341.
30. Kuerer HM, Newman LA, Smith TL: Clinical course of breast cancer patients with complete pathologic primary tumor and axillary lymph node response to doxyrubicin based neoadjuvant chemotherapy. J Clin Oncol 1999, 17:460-469.